Difference between revisions of "Infigratinib (Truseltiq)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| Line 10: | Line 10: | ||
*2021-09-27: Initial notice of compliance with conditions for the treatment of adults with previously treated, unresectable locally advanced or metastatic [[cholangiocarcinoma]] with a fibroblast growth factor receptor 2 fusion or other rearrangement. | *2021-09-27: Initial notice of compliance with conditions for the treatment of adults with previously treated, unresectable locally advanced or metastatic [[cholangiocarcinoma]] with a fibroblast growth factor receptor 2 fusion or other rearrangement. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' BGJ-398 |
*'''Brand name:''' Truseltiq | *'''Brand name:''' Truseltiq | ||
Latest revision as of 23:26, 17 August 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death.
Diseases for which it is used
History of changes in FDA indication
- 2021-05-28: Accelerated approval for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Based on CBGJ398X2204)
History of changes in Health Canada indication
- 2021-09-27: Initial notice of compliance with conditions for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement.
Also known as
- Code name: BGJ-398
- Brand name: Truseltiq